ModifiSite™ Acetylcholinesterase Inhibitor Screening Kit (CAT#: ITS-1125-WB35)

Quantifies acetylcholinesterase (AChE) inhibitor potency using a colorimetric (412 nm) method.

ModifiSite

Research-Grade Protein-Based Assay Development

The ModifiSite™ Acetylcholinesterase Inhibitor Screening Kit provides a rapid, non-radioactive solution for evaluating enzyme inhibition in drug discovery. This high-throughput compatible system utilizes an improved Ellman method to determine percent inhibition, supporting the development of therapeutic candidates for Alzheimer's and other neurological disorders by providing precise data for lead optimization and efficacy testing.

Rapid High-Sensitivity Detection: Offers a linear range of 10-600 U/L, delivering precise results within a 10-minute reaction period at ambient temperatures.
Automated HTS Compatibility: Features a homogeneous "mix-incubate-measure" format, making it ideal for large-scale liquid handling systems and automated screening platforms.
Minimal Sample Requirement: Utilizes as little as 5 µL of test compound per assay, preserving precious libraries while maintaining exceptional reproducibility.

This kit facilitates the rapid identification of potent leads to streamline hit-to-lead transitions in neuro-pharmacological drug development.

Ideal for early-stage drug discovery, chemical library profiling, and secondary screening for potency and selectivity assessment.

This assay supports high-throughput screening of chemical libraries, natural product extract evaluation, and kinetic profiling of reversible or irreversible enzyme inhibitors.

Internal performance validation using reference standards under defined assay conditions.

Targets the catalytic activity of acetylcholinesterase (AChE), the primary regulator of synaptic acetylcholine levels.

Absorbance at 412 nm

Chemical compounds

Neurodegenerative diseases, toxicology and pesticide research, neuromuscular disorders, cholinergic signaling physiology, etc.